News & Events

Island Eye is recognized as a leader in the field of surgical eye care. Many of Long Island’s premier Ophthalmic Surgeons have chosen Island Eye as the facility that they prefer when performing complicated ophthalmic surgery.

In January 2004, Island Eye completed a major building renovation to better serve our patients and visitors’ needs while at the center.

An Approved Clinical Site for Research Studies

Island Eye has become an approved clinical site for many advanced research studies on new drugs and medical devices. This is true testimony to the quality of care offered here. The site selection and approval process is very rigorous, and we are proud of our contributions to the scientific process that will ultimately enhance the visual potential of patients worldwide.

AMO Tecnis Lens

Island Eye was one of the first centers on Long Island to offer its patients the new AMO (Advanced Medical Optics) Tecnis Lens. This lens has been discussed extensively in the media for its benefit to cataract surgery patients. The Tecnis lens is the only cataract surgery lens approved by the FDA to minimize the potential for having an auto accident at night in low light conditions. This lens improves “functional vision” as well as emergency reaction time. To learn more about the Tecnis lens, you can visit www.tecnisiol.com or ask you eye doctor.

Tecnis Multifocal Lens

Island Eye has also been chosen as a site for the clinical trial of the new Tecnis Multifocal Lens. This new Tecnis lens will not only improve vision in low light conditions, but give true multifocal vision. Patients who receive this lens will have the ability to benefit from improved distance as well as reading vision. Current cataract implant lens technology primarily addresses improvements in distance vision, and patients often still require reading glasses. This is very exciting new technology and Island Eye is proud to participate in the research.

Verisyse Phakic IOL

Another recent advance in lens technology is the Verisyse Phakic IOL. This implantable lens, also manufactured by AMO, and featured in Newsday and the New York Times, corrects vision in patients who are not candidates for traditional LASIK surgery. Island Eye participated in the initial clinical research that assisted AMO in getting this lens approved by FDA. One of our surgeons, Dr. Eric Donnenfeld, was a medical monitor and the first surgeon to use this lens on Long Island. Island Eye continues in its role as a clinical training site for surgeons wishing to learn how to use this lens.